Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 60612, USA.
Parkinsonism Relat Disord. 2009 Dec;15 Suppl 3:S176-80. doi: 10.1016/S1353-8020(09)70809-0.
Growth factors are potentially major players in therapeutic interventions for neurodegenerative disorders like Parkinson's disease (PD) because of their potential to not merely provide symptomatic relief but also be disease modifying agents. Many extensively utilized therapies such as the prodrug levodopa, while unquestionably effective, are intended for symptomatic benefit. Such therapies do little to stifle the progressive nature of these diseases thereby placing temporal restrictions on their effectiveness. Growth factors, by virtue of their distinct neuroprotective properties, have the cumulative effect of curbing disease progression and allaying existing symptoms. The purpose of this review is to discuss some of the growth factors commonly used in animal models of PD and those already used in clinical trials.
生长因子在治疗帕金森病（PD）等神经退行性疾病的干预措施中可能是重要的参与者，因为它们不仅有提供症状缓解的潜力，而且还可以作为疾病修饰剂。许多广泛应用的治疗方法，如前药左旋多巴，虽然无疑是有效的，但目的是为了获得症状上的益处。这些治疗方法对抑制这些疾病的进行性特征几乎没有作用，从而对其有效性施加了时间限制。生长因子因其独特的神经保护特性，具有抑制疾病进展和缓解现有症状的累积效应。本综述的目的是讨论一些在 PD 动物模型中常用的生长因子，以及已经在临床试验中使用的生长因子。
